Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07545382). This is a study registration, not published results. Lead sponsor: Alexandria University. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 100 participants (ACTUAL). Conditions: Anticholinergic Delirium, Clozapine Poisoning, Antipsychotic Toxicity, CNS Depression, Hypoactive Delirium, Tricyclic Antidepressant Poisoning, Procyclidine Induced Delirium. Interventions: DRUG: Rivastigmine. Primary outcome measures: Change in Glasgow Coma Scale (GCS) Score. , Baseline (0 hour), 2 hours post-administration (all patients), 6-8 hours, and 12 hours (transdermal group). For patients receiving additional oral/NGT doses, assessments were repeated 2 hours after each supplemental dose up to 6 hours after resolution.; Change in Richmond Agitation-Sedation Scale (RASS) Score , Baseline, 2h (all), 6-8h & 12h (patch group), and up to 6h post-resolution (both groups). Brief summary: This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or agitated delirium. The study was conducted on 100 patients at the Poison Control Center of Alexandria University Main Hospital. The primary objective is to assess the effectiveness of rivastigmine in restoring consciousness and improving cognitive function in patients presenting with delirium and depressed mental status using GCS and RASS score.